Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection
Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection
复制标题
DOI：
10.1007/s10384-015-0411-3
复制
发表时间：
2016-01-01
影响因子：
2.4
通讯作者：
Sekiryu, Tetsuju
中科院分区：
文献类型：
--
作者：
Saito, Masaaki;Kano, Mariko;Sekiryu, Tetsuju
目的探讨玻璃体内注射阿柏西普（aflibercept）治疗息肉状脉络膜血管病变（PCV）后黄斑中心凹下厚度的变化。使用增强深度成像技术通过光学相干断层扫描（OCT）测量脉络膜厚度。玻璃体内注射阿柏西普（2 mg/0.05ml）作为负荷剂量，连续三个月注射一次，然后每两个月（每两个月）进一步注射一次。平均logMAR最佳矫正视力水平从基线时的0.40显著改善至6个月时的0.33（P < 0.001）。中心视网膜厚度从基线时的249 μ m显著降低到6个月时的161 μ m（P < 0.0001）。在6个月时，41只眼（62.1%）OCT显示黄斑干燥。在基线时有息肉样病变的46只眼中，26只眼（56.5%）在3个月时息肉样病变完全消退。Aflibercept可能有助于预防视网膜色素上皮附近或下方的脉络膜新生血管形成，与雷珠单抗相比，这可能有助于实现息肉样病变的更大闭塞。
Purpose To investigate the changes in subfoveal thickness after switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy (PCV).Methods We retrospectively reviewed 66 eyes of 65 PCV patients (mean age 75.7 years) which were refractory to ranibizumab. The choroidal thickness was measured by optical coherence tomography (OCT) using an enhanced depth imaging technique. Intravitreal aflibercept (2 mg/0.05 ml) was administered with three consecutive monthly injections as a loading dose, followed by further injections bimonthly (every two months).Results The mean subfoveal choroidal thickness significantly decreased from 203 mu m at baseline to 171 mu m at month 6 (P < 0.0001). The mean logMAR best-corrected visual acuity levels significantly improved from 0.40 at baseline to 0.33 at 6 months (P < 0.001). The central retinal thickness significantly decreased from 249 mu m at baseline to 161 mu m at 6 months (P < 0.0001). At month 6, 41 (62.1 %) eyes had dry macula by OCT. Of 46 eyes with polypoidal lesions at baseline, complete regression of polypoidal lesions was achieved in 26 (56.5 %) eyes at 3 months.Conclusions The choroidal thickness in PCV eyes significantly decreased after switching to intravitreal aflibercept injection. Aflibercept may help prevent choroidal neovascularization near or under the retinal pigment epithelium, which might help achieve greater occlusion of polypoidal lesions compared with ranibizumab.